Cargando…

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder

Olanzapine effectively treats schizophrenia and bipolar I disorder (BD-I); however, its use is limited by the risk of significant weight gain and metabolic effects. OLZ/SAM, a combination of olanzapine and samidorphan, was recently approved in the United States for the treatment of adults with schiz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Citrome, Leslie, Graham, Christine, Simmons, Adam, Jiang, Ying, Todtenkopf, Mark S, Silverman, Bernard, DiPetrillo, Lauren, Cummings, Hannah, Sun, Lei, McDonnell, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437420/ https://www.ncbi.nlm.nih.gov/pubmed/34526769 http://dx.doi.org/10.2147/NDT.S313840

Ejemplares similares

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]
Publicado: (2021)

F232. A PHASE 3 STUDY TO DETERMINE THE ANTIPSYCHOTIC EFFICACY AND SAFETY OF ALKS 3831 IN ADULT PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA
por: McDonnell, David, et al.
Publicado: (2018)

S226. A STUDY COMPARING WEIGHT GAIN FROM ALKS 3831 TO OLANZAPINE IN EARLY-ILLNESS YOUNG ADULTS WITH SCHIZOPHRENIFORM, SCHIZOPHRENIA, OR BIPOLAR I DISORDER
por: Simmons, Adam, et al.
Publicado: (2018)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
por: Citrome, Leslie, et al.
Publicado: (2019)

Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis
por: Correll, Christoph U, et al.
Publicado: (2023)

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder
por: Citrome, Leslie
Publicado: (2006)

Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting
por: Zeller, Scott L., et al.
Publicado: (2016)

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015)

Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents
por: Citrome, Leslie
Publicado: (2013)

Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
por: Faden, Justin, et al.
Publicado: (2019)

Testing the Olze and Timme Methods for Dental Age Estimation in Radiographs of Brazilian Subadults and Adults
por: Dezem, Thaís Uenoyama, et al.
Publicado: (2021)

Role of sublingual asenapine in treatment of schizophrenia
por: Citrome, Leslie
Publicado: (2011)

Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder
por: Doane, Michael J., et al.
Publicado: (2022)

Schizophrenia relapse, patient considerations, and potential role of lurasidone
por: Citrome, Leslie
Publicado: (2016)

Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
por: Citrome, Leslie, et al.
Publicado: (2022)

Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
por: Correll, Christoph U, et al.
Publicado: (2022)

Correction to: Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
por: Citrome, Leslie, et al.
Publicado: (2022)

Paliperidone: the evidence of its therapeutic value in schizophrenia
por: Kantrowitz, Joshua, et al.
Publicado: (2007)

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Citrome, Leslie
Publicado: (2018)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder
por: Citrome, Leslie, et al.
Publicado: (2017)

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Ward, Kristen, et al.
Publicado: (2019)

Olze et al. stages of radiographic visibility of root pulp and cameriere's third molar maturity index to estimate legal adult age in Hyderabad population
por: Kumar, G. Kiran, et al.
Publicado: (2019)

Increased Timing Variability in Schizophrenia and Bipolar Disorder
por: Bolbecker, Amanda R., et al.
Publicado: (2014)

Comment on “Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review”
por: Todtenkopf, Mark S., et al.
Publicado: (2023)

Prioritizing Treatment Goals of People Diagnosed with Bipolar I Disorder in the US: Best–Worst Scaling Results
por: Bridges, John F P, et al.
Publicado: (2023)

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
por: Citrome, Leslie, et al.
Publicado: (2019)

Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
por: Citrome, Leslie, et al.
Publicado: (2022)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

Perceived Burdens and Educational Needs of Caregivers of People with Schizophrenia: Results of a National Survey Study
por: Citrome, Leslie, et al.
Publicado: (2022)

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
por: Loebel, Antony, et al.
Publicado: (2015)

Pareidolia in Schizophrenia and Bipolar Disorder
por: Abo Hamza, Eid G., et al.
Publicado: (2021)

Pcdp1 is a central apparatus protein that binds Ca(2+)-calmodulin and regulates ciliary motility
por: DiPetrillo, Christen G., et al.
Publicado: (2010)

The Pcdp1 complex coordinates the activity of dynein isoforms to produce wild-type ciliary motility
por: DiPetrillo, Christen G., et al.
Publicado: (2011)

Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses
por: Zeller, Scott, et al.
Publicado: (2017)

The relationship between emotional intelligence and quality of life in schizophrenia and bipolar I disorder
por: Frajo-Apor, Beatrice, et al.
Publicado: (2021)

Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA
por: Aigbogun, Myrlene S, et al.
Publicado: (2018)

Sublingual Dexmedetomidine for the Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
por: Smith, Colin M., et al.
Publicado: (2023)

Comparing adaptive coding of reward in bipolar I disorder and schizophrenia
por: Kaliuzhna, Mariia, et al.
Publicado: (2022)

Citability of Original Research and Reviews in Journals and Their Sponsored Supplements
por: Citrome, Leslie
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_t0lqa5idoc0vnfrhi1n8jgvqdc